Covered recipient · General Payments record
CHESAHNA KINDRED WEAVER
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$31,613.55
93 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $16,987.25 | 5 |
| Honoraria | $10,002.00 | 5 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,000.00 | 1 |
| Food and Beverage | $1,545.91 | 81 |
| Education | $78.39 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES INC. | $19,537.90 | 20 |
| Lilly USA, LLC | $3,974.42 | 6 |
| PFIZER INC. | $3,056.26 | 4 |
| UCB, Inc. | $2,388.16 | 9 |
| GENZYME CORPORATION | $1,737.30 | 4 |
| AbbVie Inc. | $275.08 | 19 |
| Regeneron Healthcare Solutions, Inc. | $208.89 | 8 |
| Janssen Biotech, Inc. | $116.06 | 6 |
| Novartis Pharmaceuticals Corporation | $98.76 | 6 |
| VYNE Pharmaceuticals Inc. | $45.31 | 2 |
| LEO Pharma Inc. | $43.17 | 2 |
| Galderma Laboratories, L.P. | $42.28 | 2 |
| Incyte Corporation | $30.29 | 2 |
| Almirall LLC | $23.37 | 1 |
| Medimetriks Pharmaceuticals, Inc. | $18.76 | 1 |
| DERMIRA, INC. | $17.54 | 1 |
Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CHESAHNA KINDRED WEAVER
NPI 1518193630 · CMS profile ID 160023
Allopathic & Osteopathic Physicians / Dermatology
MARRIOTTSVILLE, MD
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1518193630?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CHESAHNA KINDRED WEAVER, NPI 1518193630, CMS profile ID 160023. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518193630?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). CHESAHNA KINDRED WEAVER, NPI 1518193630, CMS profile ID 160023. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518193630?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- CHESAHNA KINDRED WEAVER, NPI 1518193630, CMS profile ID 160023, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1518193630?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
93 matching records · $31,613.55 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–93 of 93.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| LEO Pharma Inc. | $27.37 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842215091 | CMS |
| AbbVie Inc. | $0.92 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795106943 | CMS |
| AbbVie Inc. | $18.16 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795106939 | CMS |
| Lilly USA, LLC | $2,012.50 | 05/14/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819018037 | CMS |
| Novartis Pharmaceuticals Corporation | $12.49 | 05/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812752211 | CMS |
| AbbVie Inc. | $3.63 | 05/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795106935 | CMS |
| UCB, Inc. | $2,250.00 | 05/06/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807398797 | CMS |
| Lilly USA, LLC | $21.10 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818901359 | CMS |
| Almirall LLC | $23.37 | 04/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819690901 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $9,170.00 | 04/23/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851869129 | CMS |
| PFIZER INC. | $21.03 | 04/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832709297 | CMS |
| AbbVie Inc. | $18.75 | 04/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795106931 | CMS |
| VYNE Pharmaceuticals Inc. | $21.02 | 04/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830827397 | CMS |
| Novartis Pharmaceuticals Corporation | $12.64 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812752209 | CMS |
| Janssen Biotech, Inc. | $19.48 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788336835 | CMS |
| UCB, Inc. | $14.57 | 04/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807344527 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $14.14 | 04/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851869119 | CMS |
| GENZYME CORPORATION | $21.17 | 04/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843604555 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $15.25 | 04/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851869135 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $1.25 | 03/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851869121 | CMS |
| AbbVie Inc. | $2.81 | 03/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795106927 | CMS |
| AbbVie Inc. | $16.46 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795106923 | CMS |
| Novartis Pharmaceuticals Corporation | $17.71 | 03/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812752207 | CMS |
| Janssen Biotech, Inc. | $17.26 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788336833 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $19.16 | 03/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851869111 | CMS |
| UCB, Inc. | $6.82 | 03/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807301211 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $3,552.00 | 03/10/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851869127 | CMS |
| Lilly USA, LLC | $26.87 | 03/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819018045 | CMS |
| UCB, Inc. | $23.35 | 02/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807303197 | CMS |
| UCB, Inc. | $6.67 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807320875 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $13.38 | 02/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851869109 | CMS |
| AbbVie Inc. | $22.50 | 02/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795106919 | CMS |
| VYNE Pharmaceuticals Inc. | $24.29 | 02/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830816299 | CMS |
| DERMIRA, INC. | $17.54 | 02/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 764400316 | CMS |
| Novartis Pharmaceuticals Corporation | $20.99 | 01/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812752205 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $22.51 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851869115 | CMS |
| AbbVie Inc. | $13.05 | 01/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795106917 | CMS |
| Galderma Laboratories, L.P. | $21.16 | 01/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855284569 | CMS |
| UCB, Inc. | $7.06 | 01/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807295865 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $5.53 | 01/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851869113 | CMS |
| Lilly USA, LLC | $16.73 | 01/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819004205 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $21.02 | 01/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851869147 | CMS |
| AbbVie Inc. | $23.12 | 01/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795106911 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,270.00 | 2 |
| PY2025 | Principal investigator | $205,235.87 | 176 |
| PY2024 | Recipient | $3,205.64 | 15 |
| PY2024 | Principal investigator | $273,834.27 | 88 |
| PY2023 | Recipient | $8,500.00 | 1 |
| PY2023 | Principal investigator | $40,489.18 | 17 |
| PY2022 | Principal investigator | $14,500.00 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
178 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,529.40 | 12/31/2025 | Non-covered Recipient Entity RAVEN CLINICAL RESEARCH | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata | No dispute reported | 06/30/2026 | 1202533169 |
| Principal investigator 1 | Incyte Corporation | $52.14 | 12/01/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512878 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512912 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 12/01/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512925 |
| Principal investigator 1 | Incyte Corporation | $11.45 | 12/01/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512930 |
| Principal investigator 1 | Incyte Corporation | $2,078.00 | 11/21/2025 | Non-covered Recipient Entity RAVEN CLINICAL RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240580308 |
| Principal investigator 1 | Incyte Corporation | $2,078.00 | 11/21/2025 | Non-covered Recipient Entity RAVEN CLINICAL RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240580312 |
| Principal investigator 1 | PFIZER INC. | $1,323.00 | 11/19/2025 | Non-covered Recipient Entity RAVEN CLINICAL RESEARCH INC | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228807969 |
| Principal investigator 1 | PFIZER INC. | $1,323.00 | 11/19/2025 | Non-covered Recipient Entity RAVEN CLINICAL RESEARCH INC | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228807975 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $84.16 | 11/15/2025 | Non-covered Recipient Entity CARE ACCESS MARRIOTTSVILLE | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S | No dispute reported | 06/30/2026 | 1190312873 |
| Principal investigator 1 | Incyte Corporation | $5,000.00 | 11/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512890 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 11/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512900 |
| Principal investigator 1 | Incyte Corporation | $28.00 | 11/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512904 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 11/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512922 |
| Principal investigator 1 | Incyte Corporation | $286.00 | 11/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512934 |
| Principal investigator 1 | Incyte Corporation | $2,544.00 | 11/10/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512882 |
| Principal investigator 1 | Incyte Corporation | $2,544.00 | 11/10/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512886 |
| Principal investigator 1 | ABBVIE INC. | $4,275.40 | 11/05/2025 | Non-covered Recipient Entity RAVEN CLINICAL RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202523047 |
| Principal investigator 1 | PFIZER INC. | $12,694.00 | 11/04/2025 | Non-covered Recipient Entity Raven Clinical Research Inc | A LONGTERM DOUBLEBLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031 | No dispute reported | 06/30/2026 | 1228818122 |
| Principal investigator 1 | Incyte Corporation | $15,500.00 | 10/09/2025 | Non-covered Recipient Entity RAVEN CLINICAL RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240580304 |
| Principal investigator 1 | Incyte Corporation | $1,817.00 | 10/08/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512938 |
| Principal investigator 1 | Incyte Corporation | $28.00 | 10/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512870 |
| Principal investigator 1 | Incyte Corporation | $42.00 | 10/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512874 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 10/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512893 |
| Principal investigator 1 | Incyte Corporation | $350.00 | 10/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512897 |
| Principal investigator 1 | Incyte Corporation | $54.00 | 10/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512908 |
| Principal investigator 1 | Incyte Corporation | $286.00 | 10/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512918 |
| Principal investigator 1 | PFIZER INC. | $12,694.00 | 09/24/2025 | Non-covered Recipient Entity Raven Clinical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228828489 |
| Principal investigator 1 | ABBVIE INC. | $925.74 | 09/16/2025 | Non-covered Recipient Entity RAVEN CLINICAL RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202511070 |
| Principal investigator 1 | Incyte Corporation | $286.00 | 09/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512743 |
| Principal investigator 1 | Incyte Corporation | $250.00 | 09/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512754 |
| Principal investigator 1 | Incyte Corporation | $360.00 | 09/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512761 |
| Principal investigator 1 | Incyte Corporation | $162.00 | 09/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512772 |
| Principal investigator 1 | Incyte Corporation | $168.00 | 09/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512776 |
| Principal investigator 1 | Incyte Corporation | $76.00 | 09/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512779 |
| Principal investigator 1 | Incyte Corporation | $14.00 | 09/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512784 |
| Principal investigator 1 | Incyte Corporation | $729.00 | 09/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512798 |
| Principal investigator 1 | ABBVIE INC. | $5,568.10 | 09/04/2025 | Non-covered Recipient Entity RAVEN CLINICAL RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202509108 |
| Principal investigator 1 | Incyte Corporation | $3,000.00 | 08/20/2025 | Non-covered Recipient Entity RAVEN CLINICAL RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240580300 |
| Principal investigator 1 | ABBVIE INC. | $347.50 | 08/14/2025 | Non-covered Recipient Entity RAVEN CLINICAL RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202504779 |
| Principal investigator 1 | ABBVIE INC. | $2,103.07 | 08/14/2025 | Non-covered Recipient Entity RAVEN CLINICAL RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202504793 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 08/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512789 |
| Principal investigator 1 | Incyte Corporation | $10.60 | 08/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512793 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 08/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512802 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 08/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512805 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 08/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512808 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 08/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512812 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 08/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512816 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 08/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512820 |
| Principal investigator 1 | Incyte Corporation | $1,817.00 | 08/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512824 |
| Principal investigator 1 | Incyte Corporation | $1,817.00 | 08/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512828 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 08/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512831 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 08/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512852 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 08/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512862 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 08/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512866 |
| Principal investigator 1 | Incyte Corporation | $1,203.46 | 08/01/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512645 |
| Principal investigator 1 | Incyte Corporation | $28.00 | 08/01/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512648 |
| Principal investigator 1 | Incyte Corporation | $1,817.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512655 |
| Principal investigator 1 | Incyte Corporation | $858.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512662 |
| Principal investigator 1 | Incyte Corporation | $54.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512668 |
| Principal investigator 1 | Incyte Corporation | $243.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512673 |
| Principal investigator 1 | Incyte Corporation | $42.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512679 |
| Principal investigator 1 | Incyte Corporation | $270.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512686 |
| Principal investigator 1 | Incyte Corporation | $572.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512693 |
| Principal investigator 1 | Incyte Corporation | $168.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512697 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512702 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512709 |
| Principal investigator 1 | Incyte Corporation | $2,484.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512714 |
| Principal investigator 1 | Incyte Corporation | $56.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512720 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512727 |
| Principal investigator 1 | Incyte Corporation | $3,000.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512733 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512738 |
| Principal investigator 1 | Incyte Corporation | $54.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512749 |
| Principal investigator 1 | Incyte Corporation | $56.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512765 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512769 |
| Principal investigator 1 | Incyte Corporation | $162.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512836 |
| Principal investigator 1 | Incyte Corporation | $286.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512839 |
| Principal investigator 1 | Incyte Corporation | $28.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512842 |
| Principal investigator 1 | Incyte Corporation | $1,817.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512846 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 07/09/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512850 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,250.00 | 07/02/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112461 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 07/02/2025 | Non-covered Recipient Entity UNITED CLINICAL RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223282180 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 07/02/2025 | Non-covered Recipient Entity UNITED CLINICAL RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223282190 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 06/25/2025 | Non-covered Recipient Entity UNITED CLINICAL RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223281892 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,683.02 | 06/15/2025 | Non-covered Recipient Entity KINDRED HAIR AND SKIN CENTER | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190308866 |
| Principal investigator 1 | Incyte Corporation | $1,817.00 | 06/06/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512387 |
| Principal investigator 1 | Incyte Corporation | $575.46 | 06/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512397 |
| Principal investigator 1 | Incyte Corporation | $162.00 | 06/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512403 |
| Principal investigator 1 | Incyte Corporation | $72.00 | 06/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512410 |
| Principal investigator 1 | Incyte Corporation | $139.00 | 06/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512417 |
| Principal investigator 1 | Incyte Corporation | $572.00 | 06/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512424 |
| Principal investigator 1 | Incyte Corporation | $152.00 | 06/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512430 |
| Principal investigator 1 | Incyte Corporation | $486.00 | 06/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512436 |
| Principal investigator 1 | Incyte Corporation | $210.00 | 06/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512559 |
| Principal investigator 1 | Incyte Corporation | $270.00 | 06/04/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512639 |
| Principal investigator 1 | ABBVIE INC. | $4,595.10 | 06/03/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202489205 |
| Principal investigator 1 | Incyte Corporation | $3.10 | 06/03/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512472 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 06/03/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512482 |
| Principal investigator 1 | Incyte Corporation | $82.20 | 06/03/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512507 |
| Principal investigator 1 | Incyte Corporation | $82.20 | 06/03/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512547 |
| Principal investigator 1 | Incyte Corporation | $24.30 | 06/03/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512554 |
| Principal investigator 1 | Incyte Corporation | $246.80 | 06/03/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512570 |
| Principal investigator 1 | Incyte Corporation | $2.43 | 06/03/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512586 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 06/03/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512598 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 06/03/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512603 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 06/03/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512609 |
| Principal investigator 1 | Incyte Corporation | $82.20 | 06/03/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512614 |
| Principal investigator 1 | Incyte Corporation | $82.20 | 06/03/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512622 |
| Recipient | PFIZER INC. | $940.00 | 05/30/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228828881 |
| Principal investigator 1 | ABBVIE INC. | $83.53 | 05/27/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202486285 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 05/27/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202486287 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,500.00 | 05/27/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113301 |
| Principal investigator 1 | ABBVIE INC. | $4,953.00 | 05/07/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202484059 |
| Principal investigator 1 | Incyte Corporation | $1,817.00 | 05/07/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512357 |
| Recipient | PFIZER INC. | $330.00 | 05/07/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228828951 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 05/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512486 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 05/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512492 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 05/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512498 |
| Principal investigator 1 | Incyte Corporation | $0.31 | 05/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512504 |
| Principal investigator 1 | Incyte Corporation | $17.01 | 05/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512513 |
| Principal investigator 1 | Incyte Corporation | $148.85 | 05/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512518 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 05/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512524 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 05/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512529 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 05/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512537 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 05/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512542 |
| Principal investigator 1 | Incyte Corporation | $160.30 | 05/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512591 |
| Principal investigator 1 | Incyte Corporation | $19.44 | 05/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512627 |
| Principal investigator 1 | Incyte Corporation | $2.43 | 05/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512632 |
| Principal investigator 1 | Incyte Corporation | $83.00 | 04/23/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512311 |
| Principal investigator 1 | Incyte Corporation | $108.00 | 04/23/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512321 |
| Principal investigator 1 | Incyte Corporation | $112.00 | 04/23/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512325 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 04/23/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512332 |
| Principal investigator 1 | Incyte Corporation | $42.00 | 04/23/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512366 |
| Principal investigator 1 | Incyte Corporation | $180.00 | 04/23/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512375 |
| Principal investigator 1 | Incyte Corporation | $286.00 | 04/23/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512575 |
| Principal investigator 1 | Incyte Corporation | $450.00 | 04/18/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512338 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 04/18/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512580 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 04/15/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202476539 |
| Principal investigator 1 | Incyte Corporation | $572.00 | 04/07/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512306 |
| Principal investigator 1 | Incyte Corporation | $126.00 | 04/07/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512318 |
| Principal investigator 1 | Incyte Corporation | $180.00 | 04/07/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512345 |
| Principal investigator 1 | Incyte Corporation | $1,971.00 | 04/07/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512351 |
| Principal investigator 1 | Incyte Corporation | $108.00 | 04/07/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512381 |
| Principal investigator 1 | Incyte Corporation | $262.00 | 04/07/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512565 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,044.00 | 04/04/2025 | Non-covered Recipient Entity Care Access Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175225787 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 04/03/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202471777 |
| Principal investigator 1 | ABBVIE INC. | $4,003.20 | 04/03/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202471781 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 04/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512443 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 04/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512448 |
| Principal investigator 1 | Incyte Corporation | $148.40 | 04/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512455 |
| Principal investigator 1 | Incyte Corporation | $365.70 | 04/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512461 |
| Principal investigator 1 | Incyte Corporation | $75.32 | 04/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512466 |
| Principal investigator 1 | Incyte Corporation | $84.80 | 04/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512477 |
| Principal investigator 1 | ABBVIE INC. | $150.12 | 03/25/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202465800 |
| Principal investigator 1 | Eli Lilly and Company | $1,084.80 | 03/25/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187877211 |
| Principal investigator 1 | Incyte Corporation | $1,917.00 | 03/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512233 |
| Principal investigator 1 | Incyte Corporation | $1,971.00 | 03/12/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512250 |
| Principal investigator 1 | ABBVIE INC. | $10,925.40 | 03/07/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202461431 |
| Principal investigator 1 | ABBVIE INC. | $36.14 | 02/24/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202453653 |
| Principal investigator 1 | Incyte Corporation | $1,953.00 | 02/19/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512238 |
| Principal investigator 1 | Incyte Corporation | $2,742.00 | 02/19/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512261 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,414.88 | 02/01/2025 | Non-covered Recipient Entity CARE ACCESS MARRIOTTSVILLE | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S | No dispute reported | 06/30/2026 | 1190312875 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,000.00 | 01/21/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S | No dispute reported | 06/30/2026 | 1190311135 |
| Principal investigator 1 | Incyte Corporation | $1,817.00 | 01/17/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512211 |
| Principal investigator 1 | Incyte Corporation | $1,917.00 | 01/17/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512222 |
| Principal investigator 1 | Incyte Corporation | $1,953.00 | 01/17/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512244 |
| Principal investigator 1 | PFIZER INC. | $5,000.00 | 01/17/2025 | Non-covered Recipient Entity RAVEN CLINICAL RESEARCH INC | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228713842 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 01/13/2025 | Non-covered Recipient Entity Care Access Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175226645 |
| Principal investigator 1 | Incyte Corporation | $3.41 | 01/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512216 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512227 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 01/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512255 |
| Principal investigator 1 | Incyte Corporation | $34.02 | 01/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512265 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512271 |
| Principal investigator 1 | Incyte Corporation | $123.40 | 01/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512279 |
| Principal investigator 1 | Incyte Corporation | $97.08 | 01/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512286 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512291 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512297 |
| Principal investigator 1 | Incyte Corporation | $1,083.20 | 01/02/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240512300 |